Exposure to antipsychotic medications over a 4-year period among children who initiated antipsychotic treatment before their sixth birthday

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 2, 2012, Pages 152-160

  Constantine, Robert J ^a   Jentz, Susan ^a   Bengtson, Michael ^b   Mcpherson, Marie ^a   Andel, Ross ^b,c   Jones, Mary Beth ^d  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^d Florida Agency for Health Care Administration   (United States)

Author keywords

Antipsychotic medication; Children; Long term exposure

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; COHORT ANALYSIS; DRUG EXPOSURE; DRUG USE; DRUG UTILIZATION; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAID; MOOD DISORDER; PEDIATRICS; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; PRESCHOOL CHILD; PRIORITY JOURNAL; PSYCHOTHERAPY; TREATMENT DURATION;

AGE FACTORS; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; FEMALE; FLORIDA; HUMANS; INFANT; MALE; MEDICAID; MOOD DISORDERS; RISK; TIME FACTORS; UNITED STATES;

EID: 84856301118     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2189     Document Type: Article

References (26)

1. Zito JM, Safer DJ, Valluri S, et al. Psychotherapeutic medication prevalence in Medicaid-insured preschoolers. J Child Adolesc Psychopharmacol 2007; 17: 195-203. DOI:10.1089/cap.2007.0006
2. Patel NC, Sanchez RJ, Johnsrud MT, et al. Trends in antipsychotic use in a Texas medicaid population of children and adolescents: 1996 to 2000. J Child Adolesc Psychopharmacol 2002; 12: 221-229. DOI:10.1089/104454602760386905
3. Patel NC, Crismon ML, Shafer A. Diagnoses and antipsychotic treatment among youths in a public mental health system. Ann Pharmacother 2006; 40: 205-211. DOI:10.1345/aph.1G203
4. Olfson M, Crystal S, Huang C, et al. Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry 2010; 49: 13-23. DOI:10.1016/j.jaac.2009.09.003
5. Diler R, Firat S, Avci A. An open-label trial of risperidone in children with autism. Current Therapeutic Research 2002; 63: 91-102. DOI:10.1016/S0011-393X(02)80009-1
6. Masi G, Cosenza A, Mucci M, et al. Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 2001; 40: 1206-1214. DOI:10.1097/00004583-200110000-00015
7. Gagliano A, Germanò E, Pustorino G, et al. Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc Psychopharmacol 2004; 14: 39-47. DOI: 10.1089/104454604773840472
8. Biederman J, Mick E, Hammerness P, et al. Open-Label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry 2005; 58: 589-594. DOI:10.1016/j.biopsych.2005.03.019
9. Jensen PS, Buitelaar J, Pandina GJ, et al. Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trails. Eur Child Adolesc Psychiatry 2007; 16: 104-120. DOI:10.1007/s00787-006-0580-1
10. Reyes M, Buitelaar J, Toren P, et al. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 2006; 163: 402-410. DOI:10.1176/appi.ajp.163.3.402
11. Research Units on Pediatric Psychopharmacology Autism Network (RUPP). Risperidone treatment of autistic disorder: Longer-term benefits and blinded discontinuation after 6months. Am J Psychiatry 2005; 162(7): 1361. DOI:10.1176/appi.ajp.162.7.1361
12. Luby J, Mrakotsky C, Stalets MM, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol 2006; 16: 575-587. DOI:10.1089/cap.2006.16.575
13. U. S. Food and Drug Administration. Risperidone, Aripiprazole, Quetiapine, and Olanzapine Drug Details. [14 June 2010].
14. Patel NC, Crismon ML, Hoagwood K, et al. Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents. J Child Adolesc Psychopharmacol 2005; 15: 270-284. DOI:10.1089/cap.2005.15.270
15. Coyle J. Psychotropic drug use in very young children. JAMA 2000; 283: 1059-1060. DOI: 10.1001/jama.283.8.1059
16. Gleason MM, Egger LH, Emslie GJ, et al. Psychopharmacological treatment for very young children: contexts and guidelines. J Am Acad Child Adolesc Psychiatry 2007; 46: 1532-1572. DOI:10.1097/chi.0b013e3181570d9e
17. Correll CU. Antipsychotic Use in Children. Physician's Weekly. Vol 2011.
18. Laita P, Cifuentes A, Doll A, et al. Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. J Child Adolesc Psychopharmacol 2007; 17: 487-501. DOI:10.1089/cap.2006.0039
19. Kalverdijk LJ, Tobi H, van den Berg PB, et al. Use of antipsychotic drugs among Dutch youths between 1997 and 2005. Pyschiatr Serv 2008; 59: 554-560. DOI:10.1176/appi.ps.59.5.554
20. Constantine R, Tandon R, McPherson M, et al. Early diagnoses and psychotherapeutic medication treatment experiences of a cohort of children under six years old who received antipsychotic treatment in Florida's Medicaid program. J Child Adolesc Psychopharmacol 2010;under review.
21. U.S. Food and Drug Administration: Center for Drug Evaluation and Research. National Drug Code Directory. [14 July 2010].
22. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005; 11: 449-457.
23. Brotman M, Schmajuk M, Rich BA, et al. Prevalence, clinical correlates, and longitudinal course of severe mood disregulation in children. Biol Psychiatry 2006; 60: 991-997. DOI:10.1016/j.biopsych.2006.08.042
24. De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 2011; 26: 144-158. DOI: 10.1016/j.eurpsy.2010.09.011
25. Constantine R, Larsen B. The Use of Antipsychotic Medications in Children: A Comprehensive and Current View. Louis de la Parte Florida Mental Health Institute, University of South Florida: Tampa, FL, 2007.
26. Kohlstadt I, Vitiello B. Use of atypical antipsychotics in children: balancing safety and effectiveness. Am Fam Physician 2010; 81: 585-589.